Erythropoietin/EPO Antibody (B-4): sc-5290

Epo Antibody (B-4) is a mouse monoclonal IgG2b kappa light chain antibody that detects erythropoietin (Epo) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Epo (B-4) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Erythropoietin is a crucial glycoprotein composed of 165 amino acids, primarily synthesized in the kidneys, and plays a vital role in regulating erythropoiesis, the process of red blood cell formation. This regulation is particularly important during steady-state conditions and in response to blood loss or hemorrhage, ensuring adequate oxygen delivery throughout the body. Epo achieves this by stimulating the proliferation and maturation of erythroid precursor cells in the bone marrow. The Epo receptor (EpoR), a glycoprotein found on megakaryocytes, erythroid progenitors, and endothelial cells, mediates the effects of Epo, and EpoR overexpression is linked to various pathophysiological conditions, including polycythemia vera, which arises from the Epo-independent growth of erythrocytic progenitors from abnormal stem cells. Conversely, a deficiency in Epo expression can lead to conditions such as anemia of chronic disease, commonly observed in patients with rheumatoid arthritis.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Erythropoietin/EPO Antibody (B-4) References:

1. New epoetin molecules and novel therapeutic approaches.  |  Barbone, FP., et al. 1999. Nephrol Dial Transplant. 14 Suppl 2: 80-4. PMID: 10334672
2. A potential role for erythropoietin in focal permanent cerebral ischemia in mice.  |  Bernaudin, M., et al. 1999. J Cereb Blood Flow Metab. 19: 643-51. PMID: 10366194
3. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor.  |  Dai, CH., et al. 1992. Blood. 80: 891-9. PMID: 1498332
4. Erythropoietin: structure, control of production, and function.  |  Jelkmann, W. 1992. Physiol Rev. 72: 449-89. PMID: 1557429
5. The effect of dissolved oxygen on the production and the glycosylation profile of recombinant human erythropoietin produced from CHO cells.  |  Restelli, V., et al. 2006. Biotechnol Bioeng. 94: 481-94. PMID: 16523522
6. Erythropoietin (EPO) as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of Multipotent Mesenchymal Stem Cells (MSCs): Implications in Regenerative Medicine.  |  Tsiftsoglou, AS. 2021. Cells. 10: PMID: 34440909
7. EPO prevents neuroinflammation and relieves depression via JAK/STAT signaling.  |  Luo, Y., et al. 2023. Life Sci. 333: 122102. PMID: 37769806
8. EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3.  |  Wu, G., et al. 2024. Ann Rheum Dis. 83: 564-575. PMID: 38272667
9. Characterization of three erythropoietin (Epo)-binding proteins in various human Epo-responsive cell lines and in cells transfected with human Epo-receptor cDNA.  |  Takahashi, T., et al. 1995. Blood. 85: 106-14. PMID: 7803787
10. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.  |  Ifudu, O., et al. 1996. N Engl J Med. 334: 420-5. PMID: 8552143
11. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis.  |  Lin, CS., et al. 1996. Genes Dev. 10: 154-64. PMID: 8566749
12. Role of a truncated erythropoietin receptor for erythroid differentiation.  |  Nakamura, Y., et al. 1996. Biochem Biophys Res Commun. 218: 205-9. PMID: 8573132

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Erythropoietin/EPO Antibody (B-4) has 23 citations in a variety of scientific publications.

Primary antibodies like Anti-Erythropoietin/EPO Antibody (B-4) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Erythropoietin/EPO Antibody (B-4) Specifications

Alternate Product Name: Epo

Product Clone Name: B-4

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 28-189

Epitope Target: Epo

Epitope Species: human

Product Reactivity/Detection: Epo

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 23 citations in various scientific publications

Available Conjugates/Forms for Erythropoietin/EPO Antibody (B-4): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin